Table 1.

Relationship between the expression of miR-30a and clinicopathological parameters in NSCLC.

Clinicopathological features		n	miR-30a relevant expression(2−ΔCq)
			Mean ± SD	t	P
Tissue	Adjacent non-cancerous lung	125	7.4530±3.0561	−9.707	<0.001
	NSCLC	125	4.0696±2.4178
Age (years)	<60	57	3.4649±1.9437	−2.692	0.008
	≥60	68	4.5765±2.6626
Gender	Male	75	3.7280±1.9226	−1.957	0.053
	Female	50	4.5820±2.9605
Smoking	No	38	3.6553±2.6169	0.009	0.993
	Yes	30	3.6500±2.2325
Tumor size (cm)	≤3	60	4.6417±2.7824	2.562	0.012
	>3	65	3.5415±1.8972
Lymphatic metastasis	No	56	4.8946±2.6320	3.599	<0.001
	Yes	69	3.4000±2.0103
Vascular invasion	No	90	3.9622±2.5287	−0.795	0.428
	Yes	35	4.3457±2.1150
Clinical TNM stage	I–II	54	4.9074±2.6750	3.396	0.001
	III–IV	71	3.4324±1.9961
Pathological grade	I	17	4.2529±2.9140	*F=1.497	0.228
	II	78	4.2846±2.2760
	III	30	3.4067±2.4410
Histological classification	Adenocarcinoma	101	4.4109±2.5160	*F=5.662	0.004
	Squamous carcinoma	23	2.6565±1.1739
	Large cell carcinoma	1	2.1000
EGFR amplification	No	39	3.3231±1.8688	0.177	0.860
	Yes	18	3.2278±1.9235
EGFR protein expression	low	40	3.3625±1.7624	0.427	0.671
	high	17	3.1294±2.1496
EGFR mutation	Wild type	44	3.1068±1.8520	−1.395	0.169
	Mutation**	13	3.9231±1.8606

^*One-way analysis of variance (ANOVA) test was performed;

^**EGFR mutation included short in-frame deletions in exon 19 and point mutations that result in a substitution of arginine for leucine at codon 858 (L858R) in exon 21.